⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqCM

DNTH

Dianthus Therapeutics, Inc.

Healthcare · Biotechnology

107.04USD

-2.0900 (-1.92%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End06/2026 Q2
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 107.04
P/E—
Dvd Ind Yld—
P/B5.21
P/S2,998.1
Curr EV/T12M EBITDA-23.7
Mkt Cap (USD)6.1B
Curr EV (USD)5.2B
2)

Per Share Data

EPS T12M-4.39
DPS—
Bk Val Per Sh21.39
Rev/Sh0.04
Cash/Sh15.86
Curr Shares Out55.9M
FCF/Sh-0.14
3)

Cash Flow Analysis

P/CF-39.3
Curr P/FCF-773.3
CF/NI0.8
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-7631.4%
Eff Interest Rate12.7%
4)

Growth Potential

Dil EPS 1Y Gr-64.7%
Cap 1Y Gr40.0%
BPS 1Y Gr20.8%
R&D To Sales8624.7%
Retention Rate100.0%
Rev 1Y Gr-67.3%
FCF 1Y Gr51.7%
Assets 1Y Gr42.0%
5)

Profitability

EBITDA-0.2B
EBIT-0.2B
Operating Margin-10699.6%
Pretax Margin—
Net Margin-9442.3%
ROA-25.0%
ROE-26.1%
ROC—
Asset Turnover0.00
6)

Structure

Current Ratio26.10
Quick Ratio25.79
Debt/Assets0.1%
Debt/Com Eq0.1%
Net Debt/EBITDA0.50
Tot Debt/Capital0.1%
Gross Margin100.0%
EBIT/Int Exp-1,336.5

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.